5 Ultra-High-Yield Dividend Stocks Retirees Should Buy Before December
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Retirees heading into December want income they can count on, and this list holds five dividend payers from five sectors that report solid cash coverage behind the payouts. Three of them, Verizon Communications (NYSE:VZ | VZ Price Prediction), MPLX (NYSE:MPLX) and Ares Capital (NASDAQ:ARCC), clear the 6% bar for ultra-high-yield status. Pfizer (NYSE:PFE) and Omega Healthcare Investors (NYSE:OHI) sit just under it, so we label them high-yield. Ares Capital leads the group with a forward yield of about 10.01%, based on its $1.92 annualized dividend and a share price of $19.18. We rank each name on dividend safety first and yield second.
Verizon Communications: Free Cash Flow Is Climbing Behind a 6% Payout
Verizon’s quarterly dividend is $0.7075 per share, or $2.83 annualized. At $46.68, that works out to a forward yield of about 6.06%.
Dividend safety: Third-quarter free cash flow came in at $7.801 billion[1], up 13.88% year over year, on operating cash flow of $11.517 billion. Management has now raised full-year guidance for the third consecutive quarter. Adjusted EPS is guided to $5.04 to $5.06[1], which puts the dividend at roughly 56% of the low end. Free cash flow is expected to grow close to 12%[1]. The dividend record shows a raise every year from 2021 through 2026, as the quarterly payment went from $0.6275 to $0.7075, and the supplied history shows no cuts.
Bull case: The wireless business is adding customers again. Verizon added 406,000[1] postpaid phone customers in the quarter, compared with 44,000 a year earlier. Its adjusted EBITDA margin expanded from 37.8% to 40.2%[1]. A $2 billion-plus[1] AI Connect deal with Amazon Web Services gives it a new source of growth. The stock trades at about 9x forward earnings and has a beta of 0.26, which is the kind of low-volatility profile retirees look for.
Risk: Verizon carries $166.2 billion[1] in debt. Interest expense rose 17.2% year over year, and wireless ARPA fell 1.9%.
MPLX: 1.3x Coverage on a Distribution That Keeps Growing
MPLX recently raised its quarterly distribution to $1.2111 per unit, or $4.8444 annualized. At $56.95, the forward yield is about 8.51%.
Dividend safety: Third-quarter distributable cash flow was $1.54 billion, which covered the payout 1.3x. Leverage is 3.8x, still under the partnership’s target of about 4.0x. The 12.5% raise is the third consecutive year of 12.5% increases. Over that period the quarterly payment went from $0.85 in 2024 to $0.9565, then $1.0765, then $1.2111.
Bull case: Adjusted EBITDA rose 5.3% to $1.86 billion. MPLX is spending $2.9 billion on organic growth projects, and more than 90% of that goes to natural gas and NGL assets in the Permian and Marcellus, where it expects mid-teens returns. New projects come online from 4Q26 through 2030, so the cash flow growth that supports future raises is already lined up.
Risk: MPLX sends unitholders a K-1 tax form, which makes tax filing more complicated and can cause problems inside retirement accounts. The partnership also depends heavily on its sponsor, Marathon Petroleum, and leverage ticked up from 3.7x as it pays for its capital program.
Ares Capital: 10% Yield and a Dividend Unchanged Since Early 2023
Ares Capital pays $0.48 per quarter. Its forward yield is about 10.01%, the highest on this list. The next ex-dividend date is December 15, 2026, with payment on December 29, 2026, so it’s the one stock here with an ex-dividend date still ahead in December.
Dividend safety: Ares has paid $0.48 every quarter since March 2023. Management points to 17 years of stable or rising regular quarterly dividends. The portfolio generates a weighted average yield of 10.6%, and total investment income rose 16.5%[2] to $763 million. The shares trade at 0.993 times book value, against NAV of $19.31[2] per share.
Bull case: Ares is the largest name in business development company (BDC) lending and has an investment backlog of about $2.5 billion[2]. Its pending acquisition of MidCap Financial Investment Corp adds scale. Buyers pay roughly book value for a lender that has kept its payout steady through several credit cycles.
Risk: Coverage is thin right now. Third-quarter net investment income of $0.46[2] per share came in below the $0.48 dividend. Non-accruals rose to 2.4%[2] from 1.8% at the end of 2025. New 6.25% notes are replacing 2.15% debt, which raises funding costs. If income stays below the dividend for several more quarters, the payout comes under pressure.
Pfizer: Raised Guidance Supports a High-Yield Payout
Pfizer pays $0.43 per quarter, or $1.72 a year. At $29.04, the forward yield is about 5.92%. That’s below 6%, which makes Pfizer high-yield rather than ultra-high-yield. The current ex-dividend date of November 6, 2026 has already passed, so new buyers won’t receive the December 7 payment.
Dividend safety: Pfizer raised and narrowed its adjusted EPS guidance to $2.95 to $3.05[3], which puts the dividend at about 58% of the low end. Interest coverage is 6.52x, net debt to EBITDA is 2.76x, and the free cash flow yield is 5.5%. From $0.38 in 2020 to $0.43 in 2025, the payout increased each year, then held steady through all of 2026.
Bull case: Adjusted EPS of $0.87[3] in the third quarter came in well above estimates of $0.73. Pfizer’s non-COVID portfolio grew 7%[3] operationally, led by Eliquis (up 25%) and Padcev (up 55%). Revenue guidance went up to $62.0 to $64.0 billion[3]. At about 10x forward earnings, Pfizer trades at a low multiple with exposure to an obesity and oncology pipeline.
Risk: Trailing GAAP diluted EPS of $0.70 is well below the annual dividend, and the company expects a $1.1 billion[3] revenue hit from generic and biosimilar competition this year. Paxlovid sales fell 63%[3]. Pfizer is focused on paying down debt, which explains the 2026 dividend freeze and the lack of buybacks.
Omega Healthcare Investors: Rising AFFO Puts the Dividend on Firmer Ground
Omega pays $0.68 per quarter, or $2.72 annualized. At $47.46, the forward yield is about 5.73%, which makes Omega high-yield.
Dividend safety: Omega raised its 2026 AFFO guidance to $3.28 to $3.30[4] per diluted share, up from $3.22 to $3.26. The dividend now sits at roughly 83% of the low end, a normal payout range for a REIT. Leverage is at its historically lowest level[4]. Operator EBITDAR coverage improved to 1.67x[4], and EBITDARM coverage is 2.03x. Omega paid $0.67 every quarter from January 2020 through May 2026 before raising it to $0.68 in August 2026.
Bull case: Revenue rose 9.3%[4] in the third quarter to $340.55 million. After the quarter ended, Omega committed $945.5 million[4] to new investments, including an $845.7 million U.K. mortgage loan at 8.72%[4]. Interest expense fell to $44.5 million from $58.1 million. An aging population supports long-term demand for its skilled nursing and senior housing properties.
Risk: Genesis, one of Omega’s operators, is in Chapter 11, with $148.5 million in loans outstanding (Genesis repaid $150 million in October). Changes to Medicaid and Medicare reimbursement could also pressure operator margins.
Five Income Streams Heading Into Year-End
All five of these payers back their dividends with rising cash flow or raised guidance. Verizon and MPLX offer the best combination of yield and coverage. Ares Capital gives the most income per dollar invested and still pays out in December. Pfizer and Omega trade a bit of yield for better earnings visibility. Together they spread a retiree’s income across telecom, energy, credit, pharma and healthcare real estate. Next, watch whether Ares Capital’s net investment income recovers to cover its dividend, how Genesis’s bankruptcy settles for Omega, and whether Pfizer resumes raises.
Contact [email protected] for any questions or corrections.







